Abstract
During the past decade, several high-throughput analytical methods have been developed, and most of these are being explored as potential diagnostic tools. Gene expression profiling with DNA microarrays or with multiplex polymerase chain reaction are the methods closest to being of clinical use. Prediction of clinically meaningful response to particular chemotherapy regimens or drugs remains a persistent challenge. There are established clinical and histopathologic predictors of prognosis for breast cancer, but there is no test to assist in selecting the optimal chemotherapy regimen for patients. Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Early Breast Cancer Trialists' Collaborative Group (1999) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930–942
Fisher B et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685
Rouzier R et al. (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304–1310
Buchholz TA et al. (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53: 880–888
Chen AM et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22: 2303–2312
Bonadonna G et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100
Kaufmann M et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600–2608
Smith IC et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456–1466
National Comprehensive Cancer Network, Breast Cancer Practice Guidelines (http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf)
Goldhirsch A et al. (2003) Meeting highlights: updated international expert consensus panel on the primary therapy of early breast cancer. J Clin Oncol 21: 1–9
Abu-Farsakh H et al. (1995) Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma. Breast J 1: 96–101
Colleoni M et al. (2000) Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057–1059
Kuerer HM et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460–469
Bast RC Jr et al. (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865–187875
Chang J et al. (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058–3063
Ellis P et al. (1998) Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107–114
Zhang F et al. (2003) Correlation between HER2 expression and response to neoadjuvant FAC chemotherapy in breast cancer. Cancer 97: 1758–1765
Rozan S et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27–33
Hortobagyi GN et al. In 2002 ASCO Annual Meeting Summaries; 2002 May 18-21; Orlando, FL. ASCO
Burns TF et al. (2003) Cell death signaling in malignancy. Cancer Treat Res 115: 319–343
Ramaswamy S and Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932–1941
de Bolle X and Bayliss CD (2003) Gene expression technology. Methods Mol Med 71: 135–146
Walker SJ et al. (2003) Semiquantitative real-time PCR for analysis of mRNA levels. Methods Mol Med 79: 211–227
Rajeevan MS et al. (2001) Validation of array-based gene expression profiles by real-time (kinetic) RT–PCR. J Mol Diagn 3: 26–31
Baunoch D et al.: Microarray analysis of formalin fixed paraffin-embedded tissue: the development of a gene expression staging system for breast carcinoma. In San Antonio Breast Cancer Symposium; 2003 December 3–6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic
Paik S et al.: Multi-gene RT–PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies B-20 and B-14. In San Antonio Breast Cancer Symposium; 2003 December 3–6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic
Simon R et al. (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14–18
Cui X and Churchill GA (2003) Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 4: 210
Simon R et al. (2002) Design of studies using DNA microarrays. Genet Epidemiol 23: 21–36
Sotiriou C et al. (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4: R3
Assersohn L et al. (2002) The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 8: 794–801
Pusztai L et al. (2003) Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9: 2406–2415
Ellis M et al. (2002) Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 8: 1155–1166
Symmans WF et al. (2003) Fine needle aspiration and core needle biopsy samples of breast cancer provide similar total RNA yield, but different stromal gene expression profiles cancer. Cancer 97: 2960–2971
Radmacher MD et al. (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505–511
Chang JC et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362–369
Ayers M et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 22: 2284–2293
Gianni L : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO
yoshimoto M : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO
Hannemann J : In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5–8; New Orleans. Edited by Grunberg SN. ASCO
Buchholz TA et al. (2002) Global gene expression changes during neoadjuvant chemotherapy of human breast cancer. Cancer J 8: 461–468
Mukherjee S et al. (2003) Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 10: 119–42
Chakravarthy B and Pietenpol JA (2003) Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol 30 (4 Suppl 9): 23–36
Fusaro VA and Stone JH (2003) Mass spectrometry-based proteomics and analyses of serum: a primer for the clinical investigator. Clin Exp Rheumatol 21 (6 Suppl 32): S3–S14
Pusztai L et al. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814–1822
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pusztai, L., Gianni, L. Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Rev Clin Oncol 1, 44–50 (2004). https://doi.org/10.1038/ncponc0025
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0025
This article is cited by
-
Expressions of Topoisomerase IIα and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients
Pathology & Oncology Research (2011)
-
Die Bedeutung von Mikroarrays für das Mammakarzinom
Gynäkologische Endokrinologie (2009)
-
Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables
Breast Cancer Research and Treatment (2009)
-
Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer
Clinical & Experimental Metastasis (2009)
-
Whole Genome Expression Analysis for Biologic Rational Pathway Modeling
Molecular Diagnosis & Therapy (2006)